Search results

...for Patient Safety and Quality of Virtual Careと名付けられたバーチャルケアの[[:en:patient safety organization|患者安全組織]]（PSO）を設立した。現在、[[:en:Purchase, New York|ニューヨーク州パーチェス]]に ...

...s FDA approved for weight loss but was withdrawn from the market because a safety clinical trial shows an increased occurrence of cancer. ...g Administration (FDA) approved a revised label for Xenical to include new safety information about rare cases of severe liver injury that have been reported ...

...s FDA approved for weight loss but was withdrawn from the market because a safety clinical trial shows an increased occurrence of cancer. ...g Administration (FDA) approved a revised label for Xenical to include new safety information about rare cases of severe liver injury that have been reported ...

The efficacy and safety of ipragliflozin were both observed in a [[Phases of clinical research#Phas ...tional Case Control clinical trial to see the long-term (over three years) safety of using ipragliflozin. The estimated completion of this trial is October 2 ...

The efficacy and safety of ipragliflozin were both observed in a [[Phases of clinical research#Phas ...tional Case Control clinical trial to see the long-term (over three years) safety of using ipragliflozin. The estimated completion of this trial is October 2 ...

...nsed together with a [[Medication package insert|monograph]] (in Europe, a Patient Information Leaflet or PIL) that gives detailed information about the drug. .... When purchasing a drug under the PBS, the consumer pays no more than the patient co-payment contribution, which, as of January 1, 2022, is [[Australian doll ...

...acokinetics]] or [[pharmacodynamics]]). They are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which ...bles that are substitutable with their reference product) as part of the [[Patient Protection and Affordable Care Act]] signed into law by President Obama on ...

...gy, engineering, and mathematics|STEM]] disciplines and emerging [[patient safety]] disciplines (such as [[Social work|social care research]]). ...

...acokinetics]] or [[pharmacodynamics]]). They are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which ...bles that are substitutable with their reference product) as part of the [[Patient Protection and Affordable Care Act]] signed into law by President Obama on ...

...dpoints]] of hypertension, such as heart attack, stroke and heart failure. Patient age, associated clinical conditions and end-organ damage also play a part i ...ated as first-line therapy for high blood pressure due to side effects and safety concerns, but hydralazine remains a drug of choice in [[gestational hyperte ...

...dpoints]] of hypertension, such as heart attack, stroke and heart failure. Patient age, associated clinical conditions and end-organ damage also play a part i ...ated as first-line therapy for high blood pressure due to side effects and safety concerns, but hydralazine remains a drug of choice in [[gestational hyperte ...

...[[wikt:dispense|dispense]] a specific [[prescription drug]] for a specific patient. Historically, it was a [[physician]]'s instruction to an [[apothecary]] li ...exceptional|date=June 2020}} Prescriptions also contain directions for the patient to follow when taking the drug. These directions are printed on the [[Drug ...

...unit|postanesthesia care]], a few particular steps are sufficient, and the patient's interaction with that provider is soon finished). In contrast, the word ' * [[Ambulatory care]] is care provided on an [[patient#Outpatients and inpatients|outpatient]] basis. Typically patients can walk ...

...y of risk of developing type 2 diabetes, however this trial did not report patient-relevant outcomes. Another [[systematic review]] completed in the same year ...o other treatments. This typically occurs if the dose is too high, and the patient is fasting. Some people attempt to change eating habits to prevent this, ho ...

...rmacist]] after an assessment of the patient's needs or the provision of [[patient education]]. Regulations detailing the establishments where drugs may be so ...active ingredient(s)]], [[Indication (medicine)|indication]]s and purpose, safety warnings, directions for use, and [[inactive ingredients]].<ref>[https://ww ...

...y of risk of developing type 2 diabetes, however this trial did not report patient-relevant outcomes. Another [[systematic review]] completed in the same year ...o other treatments. This typically occurs if the dose is too high, and the patient is fasting. Some people attempt to change eating habits to prevent this, ho ...

...hat physicians show consideration, compassion, and benevolence for their [[patient]]s. ...also described as specialist physicians who have sub-specialized by age of patient rather than by [[Organ (anatomy)|organ]] system. ...

...either classified as community or institutional pharmacy. Providing direct patient care in the community of institutional pharmacies is considered [[clinical ...to [[health care]] including clinical services, reviewing medications for safety and efficacy, and providing drug information. [[Pharmacist]]s, therefore, a ...

...lective and potent inhibition of SGLT-2, and its activity is based on each patient's underlying [[glycemic control|blood sugar control]] and [[kidney function ...2016 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-label-diabetes-drug-canagliflozin-invokana-invoka ...

...lective and potent inhibition of SGLT-2, and its activity is based on each patient's underlying [[glycemic control|blood sugar control]] and [[kidney function ...2016 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-label-diabetes-drug-canagliflozin-invokana-invoka ...